EcoDrugPlus

Histone Deacetylase 8

Ensembl ID : ENSFHEG00000019488
Gene Symbol: HDAC8
3 Cross references
206 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 2-Like

Ensembl ID : ENSFHEG00000001715
Gene Symbol: LOC105919080
2 Cross references
231 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSFHEG00000022576
Gene Symbol: HCN4
3 Cross references
219 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSFHEG00000009512
Gene Symbol: HCN4
3 Cross references
210 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSFHEG00000008839
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Ileal Sodium/bile Acid Cotransporter-Like

Ensembl ID : ENSFHEG00000007242
Gene Symbol: LOC105937150
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSFHEG00000007342
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSFHEG00000004178
Gene Symbol: IMPDH1
4 Cross references
258 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSFHEG00000018169
Gene Symbol: IMPDH2
4 Cross references
202 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a

Ensembl ID : ENSFHEG00000002268
Gene Symbol: LOC105938694
3 Cross references
259 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSFHEG00000009590
Gene Symbol: INPP5D
3 Cross references
216 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSFHEG00000011372
Gene Symbol: IGF1R
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).